ABHD17B

Across TCGA pan-cancer cohorts, ABHD17B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ABHD17B’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ABHD17B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ABHD17B is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

LUAD, HNSC, and PDAC are the cancer types where ABHD17B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ABHD17B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	II,III,IV	−0.290	<.001	8	view →
HNSC	All	III,IV	−0.258	<.001	8	view →
PDAC	All	All	−0.554	<.001	6	view →
CCRCC	All	III,IV	−0.188	.020	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ABHD17B–LUAD

Open the LUAD breakdown →